At the Global Think-tank on Steatotic Liver Disease, we launched the People-First Liver Charter
www.nature.com/articles/s41...

+ A call for doubling the diagnostic rate of at-risk MASH
www.thelancet.com/journals/lan...
#SLDthinktank #InMotionTogether #LiverSky

Happy to support and endorse the People First Liver Charter in
‪‪@natmed.nature.com‬‬ www.nature.com/articles/s41...

We've always taken a sensitive approach to the language used in our journal, and will continue to do so. See this Editorial www.nature.com/articles/s41...

It was a real pleasure to interview Scott Isaacs and @paulnbrennan.bsky.social regarding their recent paper on 'Anti-diabetic medications in MASLD' in Frontline Gastroenterology - listen below

fgbmj.podbean.com/e/role-of-anti-diabetic-medications-in-the-management-of-masld/

New review in #FG from @paulnbrennan.bsky.social and #scottisaacs - a great summary of the role of antidiabetic medications in MASLD #liversky

fg.bmj.com/content/earl...

The 🌎 burden of #MASH is staggering: 5.3% of adults face higher risks of cirrhosis, liver cancer & other complications as fibrosis progresses.
our latest study on MAESTRO-NASH resmetirom data & its real-world implications post-FDA approval www.nature.com/articles/s44... #SLDsummit

Autologous macrophage therapy for cirrhosis: phase 2 open-label randomized controlled trial: During 360-d follow-up, control group developed 4 liver related events, and 3 deaths (2 liver related), whereas no liver-related severe adverse events or deaths occurred in the treatment group.

The Jan 2025 issue of The Lancet Gastroenterology & Hepatology is out today at www.thelancet.com/gastrohep!

Content includes UPFs, Crohn’s disease, rectal cancer, coeliac disease, MASLD + heart disease, gastroparesis + more…

#GastroSky #LiverSky #MedSky